Loading...
XNASEYPT
Market cap491mUSD
Dec 27, Last price  
7.20USD
1D
-5.01%
1Q
-9.77%
Jan 2017
321.05%
IPO
-81.15%
Name

EyePoint Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:EYPT chart
P/E
—
P/S
10.68
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
53.12%
Rev. gr., 5y
73.10%
Revenues
46m
+11.14%
265,229629,5241,465,4232,235,0003,476,00012,162,00023,053,0004,965,0003,526,0002,143,0003,473,00026,565,0001,620,0007,539,0002,961,00020,365,00034,437,00036,939,00041,404,00046,018,000
Net income
-71m
L-43.14%
-2,559,459-11,183,322-20,913,351-103,675,000-75,670,000-2,511,0008,753,000-8,628,000-24,835,000-11,900,000-13,355,0006,347,000-21,547,000-18,485,000-53,171,000-62,969,000-52,651,000-63,915,000-124,512,000-70,795,000
CFO
2m
P
-5,435,137-9,344,112-16,138,752-21,215,000-5,143,000-8,436,0009,899,000-3,170,000-9,001,000-8,745,000-10,671,00010,297,000-16,316,000-20,490,000-21,907,000-56,699,000-14,435,000-50,097,000-65,005,0001,875,000
Earnings
Mar 05, 2025

Profile

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
URL
https://eyepointpharma.com/
IPO date
Jan 27, 2005
Employees
144
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑062017‑062016‑062015‑06
Income
Revenues
46,018
11.14%
41,404
12.09%
36,939
7.27%
Cost of revenue
121,085
118,292
89,755
Unusual Expense (Income)
NOPBT
(75,067)
(76,888)
(52,816)
NOPBT Margin
Operating Taxes
83
22,258
5,498
Tax Rate
NOPAT
(75,150)
(99,146)
(58,314)
Net income
(70,795)
-43.14%
(124,512)
94.81%
(63,915)
21.39%
Dividends
Dividend yield
Proceeds from repurchase of equity
226,174
100
216,675
BB yield
-25.16%
-0.08%
-61.56%
Debt
Debt current
10,475
782
Long-term debt
9,812
41,278
40,282
Deferred revenue
20,692
13,557
14,560
Other long-term liabilities
600
2,352
Net debt
(321,388)
(92,958)
(170,644)
Cash flow
Cash from operating activities
1,875
(65,005)
(50,097)
CAPEX
(3,483)
(2,150)
(156)
Cash from investing activities
(3,315)
(17,265)
(33,121)
Cash from financing activities
187,070
(690)
216,902
FCF
(75,161)
(103,806)
(48,871)
Balance
Cash
331,050
144,561
211,558
Long term investments
150
150
150
Excess cash
328,899
142,641
209,861
Stockholders' equity
(741,233)
96,368
184,380
Invested Capital
1,033,154
59,926
56,116
ROIC
ROCE
EV
Common stock shares outstanding
38,904
37,317
28,758
Price
23.11
560.29%
3.50
-71.41%
12.24
86.02%
Market cap
899,071
588.37%
130,610
-62.89%
351,998
316.76%
EV
577,683
37,652
181,354
EBITDA
(74,603)
(74,442)
(50,045)
EV/EBITDA
Interest
1,247
3,189
5,498
Interest/NOPBT